Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Oligometastatic bladder cancer, defined as a cancer with limited metastases, is a potential target for curative metastasis-directed therapy in a multidisciplinary framework. The consensus definition of oligometastatic bladder cancer is a valuable starting point for clinical trials, but challenges remain in accurately characterizing metastatic burden with current imaging modalities and determining optimal strategies to treat patients with lymph node involvement.
Prostate-specific membrane antigen-PET has become a valuable diagnostic tool. The second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework is the next step towards a standardized evaluation and reporting system from primary staging to reassessment of advanced prostate cancer.
The heterogeneous nature of non-muscle-invasive bladder cancer is a challenge for clinical trial design. Careful consideration in clinical trial design, choice of end points and adequate patient characterization is important when evaluating new therapies.